Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Effects of cilengitide in osteoclast maturation and behavior.

Chillà A, Bianconi D, Geetha N, Dorda A, Poettler M, Unseld M, Sykoutri D, Redlich K, Zielinski CC, Prager GW.

Exp Cell Res. 2015 Sep 10;337(1):68-75. doi: 10.1016/j.yexcr.2015.07.018. Epub 2015 Jul 21.

PMID:
26209605
2.

Nicotinic acetylcholine receptors modulate osteoclastogenesis.

Mandl P, Hayer S, Karonitsch T, Scholze P, Győri D, Sykoutri D, Blüml S, Mócsai A, Poór G, Huck S, Smolen JS, Redlich K.

Arthritis Res Ther. 2016 Mar 12;18:63. doi: 10.1186/s13075-016-0961-x.

3.

Leptin administration to overweight and obese subjects for 6 months increases free leptin concentrations but does not alter circulating hormones of the thyroid and IGF axes during weight loss induced by a mild hypocaloric diet.

Shetty GK, Matarese G, Magkos F, Moon HS, Liu X, Brennan AM, Mylvaganam G, Sykoutri D, Depaoli AM, Mantzoros CS.

Eur J Endocrinol. 2011 Aug;165(2):249-54. doi: 10.1530/EJE-11-0252. Epub 2011 May 20.

4.

Bevacizumab combined with two-weekly paclitaxel as first-line therapy for metastatic breast cancer.

Kountourakis P, Doufexis D, Maliou S, Karagiannis A, Kardara E, Margari C, Sykoutri D, Tzovaras A, Ardavanis A.

Anticancer Res. 2010 Jul;30(7):2969-71.

PMID:
20683040
5.

Paraneoplastic cerebellar degeneration in a patient with pseudomyxoma peritonei and breast cancer: case report and literature review.

Ardavanis A, Sykoutri D, Kountourakis P, Doufexis D, Korkolis D, Tzerbini H, Skarlatos I, Mosa E, Rigatos G.

In Vivo. 2009 Sep-Oct;23(5):835-8.

6.

Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review study.

Ardavanis A, Doufexis D, Kountourakis P, Malliou S, Karagiannis A, Kardara E, Sykoutri D, Charalampia M, Rigatos G.

BMC Cancer. 2009 Sep 23;9:338. doi: 10.1186/1471-2407-9-338.

7.

Bevacizumab added to the irinotecan and capecitabine combination for advanced colorectal cancer: a well-tolerated, active and convenient regimen.

Ardavanis A, Kountourakis P, Mantzaris I, Malliou S, Doufexis D, Sykoutri D, Fragos I, Rigatos G.

Anticancer Res. 2008 Sep-Oct;28(5B):3087-92.

8.

Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas.

Poulaki V, Mitsiades CS, McMullan C, Sykoutri D, Fanourakis G, Kotoula V, Tseleni-Balafouta S, Koutras DA, Mitsiades N.

J Clin Endocrinol Metab. 2003 Nov;88(11):5392-8.

PMID:
14602779
9.

Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines.

Mitsiades CS, Sykoutri D, McMullan C, Poulaki V, Mitsiades N.

J Clin Endocrinol Metab. 2003 Oct;88(10):5043-4; author reply 5044. No abstract available.

PMID:
14557495

Supplemental Content

Loading ...
Support Center